This document provides information about the 7th Annual Cold Chain Distribution for Pharmaceuticals conference taking place from September 21-24, 2009 in Philadelphia, Pennsylvania. The conference will focus on partnerships, transportation processes, risk mitigation and temperature-controlled shipment of pharmaceutical products and supplies. Topics will include re-evaluating transportation and logistics strategies, ensuring regulatory compliance, establishing qualified shipping lanes and processes, and implementing effective "last mile" logistics. The conference will feature speakers from various pharmaceutical and logistics companies and government agencies. Pre-conference discussion forums and conference tracks will address issues such as cold chain program management, new refrigeration technologies, biological materials and clinical supplies shipping, and clinical logistics.
Established in 1962 Chem Service is the largest independent supplier of Analytical Reference Materials and the original source of small quantities of organic chemicals. Chem Service also has over 2,000 Pesticide Standards, including Pesticide Standards for Cannabis in its catalogue. Chem Service offers Custom made Standards manufactured to your specific requirements, all standards are accredited to ISO 17043:2016; ISO/IEC 17025:2005; ISO 9001:2015 Quality Management System.
Over 95% of Chem Services’ neat Standards Grade materials have a purity of 98.0% or greater.
Chem Services’ worldwide customers are found in the chemical, government, food quality, agricultural and life science research communities.
In today’s drug development climate, clinical supply professionals face a unique set of challenges. These include adhering & complying with stringent regulations, using specialized temperature packaging and monitoring devices, evaluating cost-effective & validated distribution processes, shipping to and from research labs or hospitals and many more. The Clinical Logistics Supply conference will provide a unique opportunity to optimize logistics, overcome inefficiencies, develop safe vendor relationships and comply with US and international standards for your clinical supply chain.
Ws from innovation to commercialisation marcel van der sluisIventus
Presentation of dr. Marcel van der Sluis, Manager BD Drug Development Cluster at the Workshop 'From Innovation to Commercialisation' during the Dutch Life Sciences & Health Conference 2010
Hot Potato Of Responsibility Edu Quest AdvisoryEduQuest, Inc.
EduQuest Advisory for "how to manage outsourcing and not get burned" written by Martin Browning, former FDA investigator and the co-founder and president of EduQuest.
IQPC’s Partnerships for Drug Delivery Conference was designed to help pharmaceutical, biotechnology and drug delivery companies to maximize deal making potentials and mitigate risks to achieve long-term sustainability. It will provide a check-list of real life considerations for deal-making and drug delivery technology application strategies in your organization. Join us in Philadelphia on April 26-28, 2010 as we review on the latest drug delivery partnerships.
Presentation given by Dr. Rune Moen from DNV at the annual conference of the Norwegian Society for Quality and Risk Management. The presentation focuses on how to integrate Quality and Risk Management, and how to make the integrated management system operational.
Established in 1962 Chem Service is the largest independent supplier of Analytical Reference Materials and the original source of small quantities of organic chemicals. Chem Service also has over 2,000 Pesticide Standards, including Pesticide Standards for Cannabis in its catalogue. Chem Service offers Custom made Standards manufactured to your specific requirements, all standards are accredited to ISO 17043:2016; ISO/IEC 17025:2005; ISO 9001:2015 Quality Management System.
Over 95% of Chem Services’ neat Standards Grade materials have a purity of 98.0% or greater.
Chem Services’ worldwide customers are found in the chemical, government, food quality, agricultural and life science research communities.
In today’s drug development climate, clinical supply professionals face a unique set of challenges. These include adhering & complying with stringent regulations, using specialized temperature packaging and monitoring devices, evaluating cost-effective & validated distribution processes, shipping to and from research labs or hospitals and many more. The Clinical Logistics Supply conference will provide a unique opportunity to optimize logistics, overcome inefficiencies, develop safe vendor relationships and comply with US and international standards for your clinical supply chain.
Ws from innovation to commercialisation marcel van der sluisIventus
Presentation of dr. Marcel van der Sluis, Manager BD Drug Development Cluster at the Workshop 'From Innovation to Commercialisation' during the Dutch Life Sciences & Health Conference 2010
Hot Potato Of Responsibility Edu Quest AdvisoryEduQuest, Inc.
EduQuest Advisory for "how to manage outsourcing and not get burned" written by Martin Browning, former FDA investigator and the co-founder and president of EduQuest.
IQPC’s Partnerships for Drug Delivery Conference was designed to help pharmaceutical, biotechnology and drug delivery companies to maximize deal making potentials and mitigate risks to achieve long-term sustainability. It will provide a check-list of real life considerations for deal-making and drug delivery technology application strategies in your organization. Join us in Philadelphia on April 26-28, 2010 as we review on the latest drug delivery partnerships.
Presentation given by Dr. Rune Moen from DNV at the annual conference of the Norwegian Society for Quality and Risk Management. The presentation focuses on how to integrate Quality and Risk Management, and how to make the integrated management system operational.
6th Annual Cold Chain Distribution for PharmaceuticalsAbby Lombardi
The 6th Annual Cold Chain Distribution for Pharmaceuticals conference (September 2008 in Philadelphia, PA). The world's largest supply chain conference for temperature-sensitive pharmacueticals.
8th Cold Chain Management & Temperature Control SummitAbby Lombardi
Pharma IQ’s 8th Cold Chain Management & Temperature Control Summit provides the largest and most comprehensive forum for Canadian pharmaceutical, biotech and medical device professionals involved in the temperature-controlled supply chain. Attendees are able to network with and learn from other organizations who face similar challenges in monitoring, controlling, and maintaining temperatures of products throughout the supply chain – from manufacturing, warehousing, wholesalers, pharmacies, hospitals, and ultimately to the end user.
SMi proudly presents its 6th annual Cold Chain Distribution conference to be held in London on Monday 5th & Tuesday 6th of December 2011. This conference follows on from SMi’s previous highly successful Cold Chain Distribution events and offers the opportunity to keep up-to-date with the latest regulations, challenges and solutions that you need to know about for successful and cost-effective cold chain distribution
Pharma IQ’s Cold Chain & Temperature Management Summit provides the largest and most comprehensive forum for Canadian pharmaceutical, biotech and medical device professionals involved in the temperature-controlled supply chain. Attendees are able to network with and learn from other organizations who face similar challenges in monitoring, controlling, and maintaining temperatures of products throughout the supply chain. All new discussions will include: review of Health Canada’s revised <0069>, Canadian importation strategies, specialty logistics, stability data and risk mitigation.
VIBevents’ 7th Annual Cold Chain Storage and Distribution conference will bring together key manufacturers and industry experts to discuss these amongst other core issues. From understanding key transport, packaging, validation and qualification methods to optimising strategies for storing biotech and pharma products, this event will provide a platform to debate best practice approaches.
Once again, this event will be co-located with our established Clinical Trial Supply event in order to provide you with more opportunities to interact and exchange ideas with peers from both backgrounds.
PHARMACEUTICAL CONFERENCES > portfolio // Linda C. ModicaLinda Modica
This short visual presentation contains the design work of Linda C. Modica, a NYC-Metro area art director & graphic designer. Selected published works for ExL Pharma and GSMI, conference organizers.
Global competence is a function of speed, combining Program Project Management and Risk Management is important to accelerate the ability to compete worldwide. Mitigating risks in the initial phase of a new product design with supply chain involvement is essential.
6th Annual Cold Chain Distribution for PharmaceuticalsAbby Lombardi
The 6th Annual Cold Chain Distribution for Pharmaceuticals conference (September 2008 in Philadelphia, PA). The world's largest supply chain conference for temperature-sensitive pharmacueticals.
8th Cold Chain Management & Temperature Control SummitAbby Lombardi
Pharma IQ’s 8th Cold Chain Management & Temperature Control Summit provides the largest and most comprehensive forum for Canadian pharmaceutical, biotech and medical device professionals involved in the temperature-controlled supply chain. Attendees are able to network with and learn from other organizations who face similar challenges in monitoring, controlling, and maintaining temperatures of products throughout the supply chain – from manufacturing, warehousing, wholesalers, pharmacies, hospitals, and ultimately to the end user.
SMi proudly presents its 6th annual Cold Chain Distribution conference to be held in London on Monday 5th & Tuesday 6th of December 2011. This conference follows on from SMi’s previous highly successful Cold Chain Distribution events and offers the opportunity to keep up-to-date with the latest regulations, challenges and solutions that you need to know about for successful and cost-effective cold chain distribution
Pharma IQ’s Cold Chain & Temperature Management Summit provides the largest and most comprehensive forum for Canadian pharmaceutical, biotech and medical device professionals involved in the temperature-controlled supply chain. Attendees are able to network with and learn from other organizations who face similar challenges in monitoring, controlling, and maintaining temperatures of products throughout the supply chain. All new discussions will include: review of Health Canada’s revised <0069>, Canadian importation strategies, specialty logistics, stability data and risk mitigation.
VIBevents’ 7th Annual Cold Chain Storage and Distribution conference will bring together key manufacturers and industry experts to discuss these amongst other core issues. From understanding key transport, packaging, validation and qualification methods to optimising strategies for storing biotech and pharma products, this event will provide a platform to debate best practice approaches.
Once again, this event will be co-located with our established Clinical Trial Supply event in order to provide you with more opportunities to interact and exchange ideas with peers from both backgrounds.
PHARMACEUTICAL CONFERENCES > portfolio // Linda C. ModicaLinda Modica
This short visual presentation contains the design work of Linda C. Modica, a NYC-Metro area art director & graphic designer. Selected published works for ExL Pharma and GSMI, conference organizers.
Global competence is a function of speed, combining Program Project Management and Risk Management is important to accelerate the ability to compete worldwide. Mitigating risks in the initial phase of a new product design with supply chain involvement is essential.
The 8th Insurance Linked Securities Summit in Bermuda is a must attend meeting for the entire insurance-capital markets value chain including institutional investors, insurance and reinsurance companies, hedge funds, banks, law firms, underwriters and life settlement providers.
The structure of the conference – with dedicated tracks for the life and non-life sides of the market – ensures you walk away with two full days’ worth of strategies and solutions on the critical issues facing your market.
Attend Strategic Social Media for Healthcare to learn from industry visionaries on how to make the leap by taking your online presence to the next level, how to integrate new media efforts with traditional approaches and how to effectively engage with and attract current and future patient-consumers.
The 11th Annual Call Center Week is the fastest growing call center event in the world! This event designed to help companies create a customer-centric culture that inspires excellence and grows the top line. Attend Call Center Week and find out how to efficiently create a customer experience that produces engaged employees, drive performance improvement, leverage tools and social media for enhancing agent and customer satisfaction and prepare your organization for Voice of the Customer initiatives. Our practitioner speakers will share practical, measurable success stories needed to enhance business results.
IQPC’s 7th Timberland Investment Summit is the key meeting of the year for investment opportunities in the timberland asset class. Now in its 7th successful year, the conference brings together a comprehensive line-up of decision-makers from the entire timberland investments value chain including pension funds, hedge funds, endowments, family offices, TIMOs, REITs, forestry management companies, law firms, and banks.
Here’s a sneak peak at highlights of the 2010 program:
Highest ever participation from institutional investors, with speakers confirmed from Mass-PRIM, CPP Investment Board, TIAA CREF, APG, and Dallas Police & Fire Retirement System
Dedicated workshops on risk mitigation, carbon credits, and strategies for smaller investors
In-depth keynotes on the prospects for the US housing market, the macroeconomic outlook for timberland and the future of timberland values
Interactive roundtable discussions on the top 5 timberland investment opportunities
2010 promises to be an exciting year for the market. With an expanded program that includes 2 track dedicated to both insurance and longevity-linked investments, the 2nd ILS Summit Europe explores and debates the critical, providing investors with the information they need to invest effectively, profitably, and with confidence.
IQPC's 4th Annual Improving Solubility conference provides new solutions to measure, predict and improve solubility, ultimately maximizing time-to-market. Topics include applying lipid based formulations, overcoming physical instability, new drug delivery technologies, identifying in-vitro absorption and discovering formulations for toxicology studies.
3rd Life Settlements and Longevity SummitAbby Lombardi
IQPC’s 3rd Life Settlements & Longevity Summit has been specifically designed to help investors make sense of the opportunities and pitfalls of this investment class. Whether you’re an experienced investor or new to the market and still evaluating the suitability of the asset class, this conference delivers invaluable insights ensuring you make the best possible decisions for superior returns.
Topics will include: Federal Oversight New Investment Structures (Fusion and Sharia-Compliant products) Transitioning to the Tertiary market and many others!
Uncovering novel advances for increasing resistance in anti-infective drug development: The global anti-infective market is currently estimated at $66.5 billion, with anti-bacterial agents accounting for more than 50% of sales. Many biotechs and pharmaceutical companies are seeing developments in later stage clinical trials, specifically in anti-bacterial and anti-fungal, both of which are growing in demand. The threat of bacterial resistant strains of infectious diseases continually increases and creates a race to develop an effective resistant drug to combat these strains. The Anti-Infectives Summit will discuss effective lead generation approaches currently being used in anti-bacterial, anti-viral and anti-fungal drug discovery and address which biologics may play a role in anti-infective therapy.
Whether you have yet to invest in ILS, or are looking to diversify your portfolio and explore new products, the 7th Insurance Linked Securities Summit will ensure you make the right investment decisions by presenting a well-balanced perspective on the inherent risks and opportunities in the space, and the dynamic developments in technologies and tools so you can capitalize on this revolutionary asset class.
For more information, visit us at http://www.ilsnewyork.com
The Smart Metering Networking & Operations Summit provides the opportunity to exchange strategies and best practices for implementing a more stable grid – from required components to the recognition of realistic deadlines for deploying advanced technologies.
Engage with your peers to build a NEW BUSINESS MODEL for smart grid projects, ensure you are making the RIGHT INVESTMENT in technology and secure PUBLIC SUPPORT for your AMI pilots
IQPC’s 5th Forum on Laboratory Informatics will provide strategies for overcoming challenges, including:
- In-depth regulatory compliance guidance
- Extensive ELN deployment and roll out projects, focusing on ROI maximization and impact on business performance
- Informatics systems in the biobanking environment
- Proactive approaches to address challenges of integration and interfacing
- Integrating and embracing knowledge management and social media tools
IQPC’s 8th Polymorphism & Crystallization Scientific Forum is aimed at helping companies to lower costs, increase efficiency and cover a broad range of successful technical case studies on crystal nucleation and polymorphism – a major issue and area of drug development for the pharmaceutical and biotech industry.
2nd Life Settlements & Longevity SummitAbby Lombardi
IQPC’s 2nd Life Settlements & Longevity Summit has been specifically designed to help you – the investor – make sense of the opportunities and pitfalls of this exciting investment class. With more seniors turning to life settlement options and the need to diversify with an uncorrelated asset, 2009 has been a year of opportunity in these investments. However, following the life expectancy revision in 2008, many investors lost money on their portfolios and there remains widespread uncertainty regarding LEs currently in place. Whether you’re an experienced investor or new to the market and still evaluating the suitability of the asset class, this conference delivers invaluable insights from investors, fund managers, and industry experts, ensuring you make the best possible decisions for superior returns.
8th Lean Six Sigma for Pharmaceutical, Biotech & Medical Device ExcellenceAbby Lombardi
At the 8th Lean Six Sigma for Pharma, we will bring you real-world case studies that tackle the problems you are encountering, provide you with real-world solutions, and introduce you to industry peers who have been able to overcome many of the challenges Lean Six Sigma presents.
Walk away with tools for practical applications of Lean Six Sigma in R&D, transactional, business and training processes as well as along the supply chain.
2009 is a crucial year for the insurance linked securities market, with positive developments – including the issuance of new bonds from SCOR, Chubb, and Liberty Mutual. The 6th ILS Summit will discuss the need for enhanced transparency, reduced counterparty risk and better valuations which investors are demanding to ensure the long term future of the sector. It’s the largest ILS conference in the world, with more delegates, speakers, opportunities for networking than any other event.
The 16th Annual Kid Power! conference brings together the leading brands, agencies, media and strategists to discuss the best ways of reaching not just kids, but the whole family & the “whole child”.
Highlights from Kid Power 2009 include:
- Explore new technologies – like social networking and mobile marketing – and how to use them successfully
- Find the keys to reaching kids and what they really want
- Hear specific research results and trend analysis
- Learn about new research and case studies on reaching moms, dads, grandparents and other family members
- Network with marketing, branding and innovative leaders in the “kid space”
New Drug Discovery and Development .....NEHA GUPTA
The "New Drug Discovery and Development" process involves the identification, design, testing, and manufacturing of novel pharmaceutical compounds with the aim of introducing new and improved treatments for various medical conditions. This comprehensive endeavor encompasses various stages, including target identification, preclinical studies, clinical trials, regulatory approval, and post-market surveillance. It involves multidisciplinary collaboration among scientists, researchers, clinicians, regulatory experts, and pharmaceutical companies to bring innovative therapies to market and address unmet medical needs.
micro teaching on communication m.sc nursing.pdfAnurag Sharma
Microteaching is a unique model of practice teaching. It is a viable instrument for the. desired change in the teaching behavior or the behavior potential which, in specified types of real. classroom situations, tends to facilitate the achievement of specified types of objectives.
CDSCO and Phamacovigilance {Regulatory body in India}NEHA GUPTA
The Central Drugs Standard Control Organization (CDSCO) is India's national regulatory body for pharmaceuticals and medical devices. Operating under the Directorate General of Health Services, Ministry of Health & Family Welfare, Government of India, the CDSCO is responsible for approving new drugs, conducting clinical trials, setting standards for drugs, controlling the quality of imported drugs, and coordinating the activities of State Drug Control Organizations by providing expert advice.
Pharmacovigilance, on the other hand, is the science and activities related to the detection, assessment, understanding, and prevention of adverse effects or any other drug-related problems. The primary aim of pharmacovigilance is to ensure the safety and efficacy of medicines, thereby protecting public health.
In India, pharmacovigilance activities are monitored by the Pharmacovigilance Programme of India (PvPI), which works closely with CDSCO to collect, analyze, and act upon data regarding adverse drug reactions (ADRs). Together, they play a critical role in ensuring that the benefits of drugs outweigh their risks, maintaining high standards of patient safety, and promoting the rational use of medicines.
- Video recording of this lecture in English language: https://youtu.be/kqbnxVAZs-0
- Video recording of this lecture in Arabic language: https://youtu.be/SINlygW1Mpc
- Link to download the book free: https://nephrotube.blogspot.com/p/nephrotube-nephrology-books.html
- Link to NephroTube website: www.NephroTube.com
- Link to NephroTube social media accounts: https://nephrotube.blogspot.com/p/join-nephrotube-on-social-media.html
Local Advanced Lung Cancer: Artificial Intelligence, Synergetics, Complex Sys...Oleg Kshivets
Overall life span (LS) was 1671.7±1721.6 days and cumulative 5YS reached 62.4%, 10 years – 50.4%, 20 years – 44.6%. 94 LCP lived more than 5 years without cancer (LS=2958.6±1723.6 days), 22 – more than 10 years (LS=5571±1841.8 days). 67 LCP died because of LC (LS=471.9±344 days). AT significantly improved 5YS (68% vs. 53.7%) (P=0.028 by log-rank test). Cox modeling displayed that 5YS of LCP significantly depended on: N0-N12, T3-4, blood cell circuit, cell ratio factors (ratio between cancer cells-CC and blood cells subpopulations), LC cell dynamics, recalcification time, heparin tolerance, prothrombin index, protein, AT, procedure type (P=0.000-0.031). Neural networks, genetic algorithm selection and bootstrap simulation revealed relationships between 5YS and N0-12 (rank=1), thrombocytes/CC (rank=2), segmented neutrophils/CC (3), eosinophils/CC (4), erythrocytes/CC (5), healthy cells/CC (6), lymphocytes/CC (7), stick neutrophils/CC (8), leucocytes/CC (9), monocytes/CC (10). Correct prediction of 5YS was 100% by neural networks computing (error=0.000; area under ROC curve=1.0).
Title: Sense of Taste
Presenter: Dr. Faiza, Assistant Professor of Physiology
Qualifications:
MBBS (Best Graduate, AIMC Lahore)
FCPS Physiology
ICMT, CHPE, DHPE (STMU)
MPH (GC University, Faisalabad)
MBA (Virtual University of Pakistan)
Learning Objectives:
Describe the structure and function of taste buds.
Describe the relationship between the taste threshold and taste index of common substances.
Explain the chemical basis and signal transduction of taste perception for each type of primary taste sensation.
Recognize different abnormalities of taste perception and their causes.
Key Topics:
Significance of Taste Sensation:
Differentiation between pleasant and harmful food
Influence on behavior
Selection of food based on metabolic needs
Receptors of Taste:
Taste buds on the tongue
Influence of sense of smell, texture of food, and pain stimulation (e.g., by pepper)
Primary and Secondary Taste Sensations:
Primary taste sensations: Sweet, Sour, Salty, Bitter, Umami
Chemical basis and signal transduction mechanisms for each taste
Taste Threshold and Index:
Taste threshold values for Sweet (sucrose), Salty (NaCl), Sour (HCl), and Bitter (Quinine)
Taste index relationship: Inversely proportional to taste threshold
Taste Blindness:
Inability to taste certain substances, particularly thiourea compounds
Example: Phenylthiocarbamide
Structure and Function of Taste Buds:
Composition: Epithelial cells, Sustentacular/Supporting cells, Taste cells, Basal cells
Features: Taste pores, Taste hairs/microvilli, and Taste nerve fibers
Location of Taste Buds:
Found in papillae of the tongue (Fungiform, Circumvallate, Foliate)
Also present on the palate, tonsillar pillars, epiglottis, and proximal esophagus
Mechanism of Taste Stimulation:
Interaction of taste substances with receptors on microvilli
Signal transduction pathways for Umami, Sweet, Bitter, Sour, and Salty tastes
Taste Sensitivity and Adaptation:
Decrease in sensitivity with age
Rapid adaptation of taste sensation
Role of Saliva in Taste:
Dissolution of tastants to reach receptors
Washing away the stimulus
Taste Preferences and Aversions:
Mechanisms behind taste preference and aversion
Influence of receptors and neural pathways
Impact of Sensory Nerve Damage:
Degeneration of taste buds if the sensory nerve fiber is cut
Abnormalities of Taste Detection:
Conditions: Ageusia, Hypogeusia, Dysgeusia (parageusia)
Causes: Nerve damage, neurological disorders, infections, poor oral hygiene, adverse drug effects, deficiencies, aging, tobacco use, altered neurotransmitter levels
Neurotransmitters and Taste Threshold:
Effects of serotonin (5-HT) and norepinephrine (NE) on taste sensitivity
Supertasters:
25% of the population with heightened sensitivity to taste, especially bitterness
Increased number of fungiform papillae
1. The World’s Largest Global Forum for Cold
Chain Specialists – Sold out in the US, Canada,
Belgium, UK, Brazil, Singapore and Germany
Solid Partnerships, Transport Processes and Risk September 21 – 24, 2009
Mitigation for Cost-Effective Temperature Pennsylvania Convention Center
Controlled Shipment of Products and Supplies Philadelphia, PA
Top 5 Reasons to Attend: Attend the industry’s favorite
• Re-evaluate your transportation & logistics strategy to cold chain event and learn from
ensure cost-effectiveness and streamlined processes
35+ top professionals, including:
• Ensure compliance of international & domestic
regulations of temperature-sensitive products and Keynote: Edward J. Kelley, General
supplies through risk assessment & stability case studies Manager for Air Cargo, U.S. Dept. of
• Establish qualified lanes, packaging and processes to Homeland Security – “TSA Screening
internationally ship your new high-value vaccines, blood Cargo Program”
products and biological materials
Rafik H. Bishara, PhD, Technical Advisor and
• Implement effective last mile logistics processes to Chair PCCIG USA Branch, PDA
ensure product integrity to the patient and to remote
Ian Holloway, Manager, Defective Medicines
destinations Report Centre, MHRA
• Network with 350+ professionals from manufacturing, Sarah Skuce, Compliance Specialist, Health
logistics, packaging, QA, regulatory agencies, wholesale Canada
and logistics and freight partners Bob Seevers, Principal Regulatory Scientist,
Regulatory Affairs, CMC, Eli Lilly and
Company
ALL NEW, for you: Cold Chain Distribution 2009 Anthony Moran, Director of Procurement,
Siemens
New industry sector and cold chain stakeholder perspectives from: Joanna Ward, Senior Director, Manufacturing
and Supply Chain Management, Seattle
Genetics Research Biotech R&D McKesson Wholesalers
Genetics
Animal Health Insurance Underwriter Novartis Clint Pollard, Manager, Transportation, Merial
Medical Devices US Military American Red Cross Animal Health
Geoff Glauser, Director of Global Packaging
Plus - Hear how Cathay Pacific, Air France/KLM, American and Delta meet new IATA Technology, Wyeth
guidelines and TSA Screening Security requirements Rose Bicksler, Senior Manager, Global Quality
Assurance and Validation, Johnson & Johnson
Vincent Porzio, Clinical Supplies Manager,
Don’t miss the new Clinical Register by July 10th and Schering-Plough
Claude Jolicoeur, Director of Regulatory Affairs
Logistics Focus Day SAVE up to $2,595 and Corporate GMP Officer, McKesson Canada
Corp.
Sponsors:
www.coldchainpharma.com
2. September 21 – 24, 2009
Pennsylvania Convention Center
Philadelphia, PA
Solid Partnerships, Transport Processes and Risk Mitigation for Cost-Effective Temperature
Controlled Shipment of Products and Supplies
Table of Contents:
Dear Colleague,
Pre-Conference Specialist
The ‘cold chain’ we used to know Discussion Forums . . . . . . . . . . . . . . 5-6
is history. Today, biopharmas, med
and other organizations face new ical device Transportation &
challenges controlling, monitoring
mitigating risk involved in transpor and Logistics Plenary Sessions . . . . . . . . . . 7
ting & distributing temperature-sen
products. Regulators require tem sitive
perature control of many tempera Biological Materials &
cost pressures are forcing compan ture ranges,
ies to re-evaluate their transportatio Clinical Supplies Track . . . . . . . . . . . . . 8
strategy, revised modes of transpor n
t require new risk profiles, and mor
biological drugs are entering internat e Last Mile Cold Chain Logistics Track. . 8
ional trials and the market.
Regulatory Compliance
At the 7th Annual Cold Chain Dist Plenary Sessions . . . . . . . . . . . . . . . . . 9
ribution for Pharmaceuticals, you
learn from expert speakers and indu will
stry colleagues through case-studies QA Distribution &
discussions and plenary sessions how , panel
to update your temperature control Risk Management Track . . . . . . . . . . . 9
logistics and QA to meet today’s chal
lenges. In addition, you’ll compare
quality initiatives, transportation strat new Cold Chain Packaging
egies and qualified packaging whic & Materials Track . . . . . . . . . . . . . . . . 9
more control, increased compliance h offer
and efficiency for international distr
of cold chain products, IMPs and ibution Clinical Logistics Focus Day . . . . . . . . 11
bulk material.
As always, peer-to-peer networki About Our Sponsors . . . . . . . . . . 12-13
ng is at its best at Pharma IQ’s
event as: annual Venue & Accommodations . . . . . . . . 14
•
The largest cold chain show, bringing Pricing & Registration Information. . . 15
together 350+ temperature control
supply, logistics, packaging, IT and
QA professionals
•
A ‘one stop shop’ exhibition for part
icipants to consult with 40+ new
existing cold chain partners in tran or
sport, packaging, freight forwardi A special thank you to our
information systems ng and
2009 Executive Advisory
Time out of the office is sometimes
peers – if you’re going to attend one
hard to come by, however just ask
your Board:
Cold Chain conference this year –
industry’s choice for the best educatio the Rafik H. Bishara, PhD, Technical Advisor and
nal value and networking opportu
Pharma IQ’s Cold Chain event in Phila nity is Chair PCCIG USA Branch, PDA
delphia.
Geoff Glauser, Director of Global Packaging
The speakers, sponsors and Pharma Technology, Wyeth
IQ team look forward to seeing you
September in Philadelphia for the in
7th Annual Cold Chain Distribution Kevin O'Donnell, Chief Technical Officer,
Pharmaceuticals 2009 conference. for
Thermosafe & Author
www.coolerheadsblog.com
Sincerely,
Karl Kussow, Manager, Quality and Validation,
FedEx Custom Critical
Gwyn Murdoch, Quality Manager,
Materials/Packaging Quality Systems, Eli Lilly
Jim Bacon, Director, Global Demand Planning
and Customer Service, Talecris
PS: Don’t miss
Courtney Becker-James th Bobby Boehm, Associate Director, Cold Chain,
Conference Director Clinical Logistics e new Bristol Myers Squibb
Day! See page Focus
Pharma IQ, a division of IQPC Rich Ellinger, Director of Global Marketing and
www.coldchainpharma.com Business Development, Tegrant Corporation
courtney.becker@iqpc.co.uk 11 for
details. Nick Basta, Editor in Chief, Pharmaceutical
Commerce
2 www.coldchainpharma.com
3. What’s New for
Clinical Logistics Focus Day
Smaller validated packaging, countless clinical sites, patient cold chain
compliance, site practitioner issues… the list continues for the unique
challenges faced by Clinical Supply professionals. Join us for a focused day
on how to cost-effectively and compliantly ship clinical materials and
comparators for international clinical trials.
“Implementing Automated Temperature Monitoring to Improve Clinical
Distribution Processes” - Schering-Plough
“Best Practices to Improve Patient and Clinical Site Cold Chain
Compliance” - Bernstein CMC Regulatory Consulting
“Case Study: Managing a Massive Large Scale Vaccine Clinical Trial”
- Wyeth
Transportation and Logistics Plenary
Keynote: Edward J. Kelley, U.S. Dept. of Homeland Security
“Qualifying for the TSA Cargo Screening Program”
Interview with Airlines
Hear how leading carries including Cathay Pacific, Air France/KLM, American
and Delta are updating their processes to meet updated IATA Chapter 17
*Don’t miss the ‘hot topic’ workshop*
“Quality and Efficiency for Cost & Temperature Controlled
Transportation”
Last Mile Logistics
“Role of the Wholesaler in the Distribution Of Temperature-Controlled
Products” - McKesson
“Distribution of Cold Chain Products to the Public and Emergency
Planning” - Public Health District Leader, Alexandria, Virginia
Biological Materials & Clinical Supplies
“Quality Control for the Storage and Transportation of Blood and
Biologics” - American Red Cross
“Global Logistics for the Clinical Distribution of Cytotoxic
Antibody-Drug Conjugates” - Seattle Genetics
“Cold Chain Planning and Shipping of Bulk Protein Internationally
at -60°C” - Novartis
3
4. More than 150 different companies attended Cold Chain Distribution 2008 including:
Abbott Laboratories Global Pharmaceutical Supply Group
AcuTemp Thermal Systems Hamilton Park Capital
Alexion Pharmaceuticals Inc Health Canada
Almac Group An eye opener on several Immunogen Inc
Altus Pharmaceuticals Impeva Labs
American Thermal Instruments Inc. topics. I enjoyed both Integra Lifesciences Corporation
Amgen Inc Janseen-Cilag
Amylin Pharmaceuticals Inc days and would JeanCoutu Pharmacy
Anesiva Inc. Johnon & Johnson Sales & Logistics Co.
APP Pharmaceuticals recommend such an event Johnson Matthey Pharma Materials
AstraZeneca Pharmaceuticals JOM Pharmaceutical Services Inc
ATL Pharma Security Label Systems to other colleagues. Also, Kirin Pharma USA Inc
Auxilium Pharmaceuticals Inc Kryotrans
Bausch & Lomb networking was great! Kuehne Nagel Inc
Bax Global Lanter Distribution
Baxter Healthcare Lantheus Medical Imaging
Bayer Corp.
– Program Manager of Quality Life Packaging Technology
Bayer HealthCare Assurance Compliance, Abbott Lifoam Industries, LLC
BioMarin Pharmaceutical MannKind Corporation
BioMérieux Inc Laboratories MAYA Simulation Technologies, Ltd.
Blue Vector Medarex, Inc
BlueBird Express Medco Health Services
Boston Scientific Medicis Pharmaceutical Corp
Bressler Group MedImmune Inc
Bristol Myers Squibb Medtronic Spinal & Biologics
Brookwood Pharmaceuticals Mellenium
Burris Logistics
Cangene Corporation
The subject matter was Mentor Biologics
Merck and Company
Cardinal Health
Catalent Pharma Solutions
excellent and covered all Merial Limited
Minnesota Thermal Science
Cathay Pacific Airways
CBMS Chemical Biological Medical Systems
aspects of what to do and Myoderm Medical
NanoCool
Celgene Corp
Centocor
what is on the horizon for Novartis Pharmaceuticals
NovaRx
Centocor R&D
Cephalon Inc
companies in the next Onqor
Packaging Science Resources
CEVA Freight Management - RDU
Chick Packaging Group
few years. IQPC staff PackagingPrice Inc
Pakoil
Climate Controlled Containers Inc Panther Expedited Services
Cold Chain Technologies
really put together an Perrigo
Covidien Pfizer
CSafe LLC action-packed conference Polyair
CSL Behring Pop Technology
Cubist Pharmaceuticals and managed well. Priority Solutions
Dawson Logistics Quality Solutions
Defense Supply Center-Philadelphia – Director, Pharmaceutical Rand-Whitney Container
DeltaTRAK Sanofi Pasteur Ltd.
Dentsply International Packaging Services, Schering- Schering-Plough Corporation
DHS U.S. Immigration & Customs Sensitech
Enforcement Plough Corporation Sentry Logistic Solutions
DoubleDay Holdings Shire Pharmaceuticals
EDUQUEST SNC Lavalin Pharma
Elan Pharmaceuticals, Inc. Takeda Pharmaceutical
Eli Lilly and Company Talecris Biotherapeutics, Inc.
Elpro Services TCP Reliable
Emergent BioDefense Operations Lansing Tegrant Thermosafe Brands
Envirotainer Very good speakers and TempTime Corporation
Ernest Packaging Solutions Teva Pharmaceuticals USA , Inc.
Falvey Cargo Underwriters subject matter and was Thermal Packaging Solutions
FedEx Tucker Company
Fisher Bio Services filled with information uniPHARM Wholesale Drugs
Fisher Clinical Services University of Florida
Flexpoint rather than basic UPS
Frontier Paper US Pharmacopeia
FUJIREBIO INC
GBSC LLC - J&J
concepts. USPack Courier Service
UTI
Gene News
Genetech
– Logistics Project Manager, ViroPharma
Wal-Mart Specialty Pharmacy
Genvec
Genzyme Corporation
Bilcare, Inc. Willerup Consulting, LLC
World Courier
Gilbert’s LLP Wyeth Pharmaceuticals
Gilead Sciences Xdicator Corporate
GlaxoSmithKline ZLB Plasma
4 www.coldchainpharma.com Sponsors:
5. Pre-Conference Specialist Discussion Forums
Monday, September 21, 2009
8:00 am – 11:00 am Registration at 7:45 (Coffee will be served)
A Cold Chain Program Management: Utilizing Temperature Information for Continuous
Process Improvements
Performing a cold chain audit is the first step in identifying potential risks in a • Statistically evaluating supply chain processes with the goal of improving supply
temperature-sensitive supply chain. Second, banking cold chain data and chain performance and overall efficiency
statistically evaluating supply chain performance over time enables the • Food industry examples driven by customer retention and product quality
development of continuous process improvement programs. Third, knowledge of
What you will learn:
the global regulatory and industry standard guidance for the storage, handling • Apply a risk-based approach grounded in industry guidance and driven by
and distribution of temperature sensitive medicinal products is critical to
process validation for insuring overall cold chain compliance
protecting patient safety.
Choose from Workshop A or B
• Drive efficiency and reduce costs while meeting regulatory requirements
How you will benefit: • Document and mitigate risks through the development of improved
This workshop will address the above three key elements together in an • Standard Operating Procedures (SOPs) – while driving improved efficiencies and
interactive and thoughtful discussion linked to specific case studies, including lowering overall costs
examination of:
• Temperature-sensitive risk assessment Your Workshop Leaders:
• Developing a cold chain program the identifies process trends and utilizes Henry Ames, Director of Strategic Marketing, Sensitech
shipping reports to feed into continuous improvement efforts Mark Maurice, Project Manager, Sensitech
• Meeting Quality defined storage requirements
8:00 am – 11:00 am Registration at 7:45 (Coffee will be served)
B Leveraging New Refrigerant Technologies: Use of Engineered Phase Change Materials
in Cold Chain Packaging Design
What you will learn: • How traditional water based refrigerants are best utilized and what are their
• Alternatives to traditional gel pack refrigerants available in the industry true limitations
• How to identify and evaluate the trade-offs in material costs v. the total costs of • How engineered phase materials can contribute to your company sustainability
the packaging and distribution initiatives
• Performance variables to consider in the selection of a PCM • Re-usability v. Single use? What types of applications are engineered PCM’s best
deployed?
How you will benefit:
Through case studies interaction with packaging and logistics peers, you will go Your Workshop Leader:
through examples to understand: Anthony Alleva, Technical Services Manager, TCP Reliable/Cryopak
11:15 am – 2:15 pm Registration at 11:00 (Lunch will be served)
C Sea Transportation of Temperature Controlled Pharmaceutical Products
How you will benefit:
What you will learn: Through discussions and case scenarios of sea transport, you will discuss with your
• Current reefers on the market that afford cost-effective, low risk options for
industry colleagues and those experienced with sea transport, how to:
transporting pharmaceutical products • Attain buy in from senior management and colleagues in quality management
• Compare efficiency vs. cost of sea transport to other modes • Define common ground and ways to work effectively with sea carriers
• Risks of sea transport: Examining risks with longer routes, port authorities and • Developing SOPs with ocean carriers
various other handlers • Implement proactive contingency plans
• Understand what sea carriers offer competitive services for transport of
temperature controlled pharmaceuticals Workshop leader to be announced. Please check www.coldchainpharma.com for
updates.
Choose from Workshop C or D
11:15 am – 2:15 pm Registration at 11:00 (Lunch will be served)
D Which Shipping Solution is Greener? What You Measure Might Surprise You!
Using Science and Data-Driven Decisions When Choosing Among How you will benefit:
Green Cold Chain Shipping and Logistics Options Through case examples and interactive exercises, you will discuss with the CCT
Appropriately, companies are placing more and more emphasis on utilizing and MIT team how to:
“green”, “sustainable”, “reusable” and/or “recyclable” shipping and logistics • Evaluate green and sustainable packaging and logistics options
solutions for their cold chain packaging and distribution needs. The difficulty arises • Consider the value proposition for environmentally-friendly choices
in putting hard measurements around the level of “green-ness” or sustainability, • Better understand the practicalities of using green packaging
attributes whose very definitions are subject to wide interpretation. In conjunction • Develop a measurement model to fit your needs
with a team from the Massachusetts Institute of Technology (MIT), Cold Chain
Your Workshop Leaders:
Technologies (CCT) has developed a data-driven and dynamic model to help
Anthony “TJ” Rizzo, Strategic Account Engineer, Cold Chain Technologies
evaluate product delivery options in terms of both logistics costs and
environmental impact, using derived, hard values. Bob Bohne, VP & General Manager, Cold Chain Technologies
What you will learn: Jeremy Stewart, Leaders for Global Operations Fellow, Massachusetts
• Life Cycle Analysis Institute of Technology
• State-of-the-art approaches to sustainability Angelo Capuzzi, Leaders for Global Operations Fellow, Massachusetts
• Measurement methods and values for measuring environmental impact Institute of Technology
• Case Study: Evaluating various high-volume refrigerant delivery method options
• Approaches for developing your own model
5
6. 2:30 pm – 5:30 pm Registration at 2:15
E Quality and Efficiency for Cost & Temperature Controlled Transportation
The workshop will facilitate a discussion of considerations for choosing a How you will benefit:
transportation method, including international regulations, shipping environments, Through case studies of real-life examples and interactive exercises, you will
and the strengths and weaknesses of available temperature control options for air understand how transport systems can be designed to significantly reduce or
and ground transport. eliminate common problems in domestic US and international air transport. You will
The group will discuss solution options and criteria for designing best practice gain an appreciation for the relative costs and benefits of achieving your
transportation systems and procedures that appropriately blend the needs of your transportation objectives within the framework of your GDP requirements and
product, your business, and available services. We will also explore the effectiveness discuss how to minimize those costs while maintaining safe transport requirements.
of various choices by considering case studies for both ground and air transport. • Improve your ability to implement high quality, secure, and cost-effective
transportation
What you will learn:
Choose from Workshop E or F
• Enhance your ability to apply industry and governmental guidance on Good
Gain insight into carrier quality systems for both standard transportation and
Distribution Practices in your transportation plans
temperature control including: • Increase your understanding of how to effectively work with your carrier to
• Strategies for implementing best practices for achieving high quality and safety in
maximize the quality, consistency, and economy of your shipping lane
both air and ground transport
• Effective procedures to address transport risk issues Your Workshop Leader:
• Decision making factors for evaluating cost-effective transportation strategies for Karl Kussow, Manager, Quality, FedEx Custom Critical
cold chain
2:30 pm – 5:30 pm Registration at 2:15
F Examining the Impact of Packaging and Shipping on Supply Chain Integrity for
Vaccines and Challenging Destinations
The Department of Defense has unique challenges which require more stringent sometimes remote unit such as mobile hospitals, field paramedics and combat
temperature controls, delivery time pressures and sometimes difficult to reach zones
destinations. This workshop is a unique opportunity to learn from the US • How to establish processes for emergencies and working within defined timelines
Department of Defense’s Cold Chain Manager how to ensure effective, safe and • Working with specialty carriers for bio materials
compliant shipping of vaccines and biomaterials.
How you will benefit:
What you will learn: • Balance cost pressure with time and temperature requirements to find suitable
• The role of appropriate packaging and transportation handling in the supply chain packaging
to maintain Cold Chain Integrity • Understand different packaging requirements for temperature controlled
• How to choose packaging solutions and vendors to ensure quality substances
• Passive, small parcel, refrigerated packaging protocols • Understand specific challenges in the US Military Supply Chain as a military
• Passive, “disposable,” bulk shipper with validated pack-outs for all 3 personnel yourself or as a key supply partner
temperature range requirements
• Alternatives to passive packaging Your Workshop Leader:
• Logistical challenges in shipping supplies to international destination and Ms. Dana L. Dallas, Vaccine/Cold Chain Program Manager, Defense Supply
Center Philadelphia
5:45 pm – 8:45 pm Registration at 5:30 (Dinner will be served)
G Bringing Your Logistic Operations to Meet Today’s Airline Cargo and
Transportation Security Challenges
Maximizing supply-chain value may depend on how well you are navigating new How you will benefit:
complexities regarding airline security, international importation, customs and cold- Through case examples and one-on-one discussion, you will interact with leading
chain options in global pharmaceutical transport. This workshop will feature insights aviation and security experts from American Airlines, the Transportation Security
on these issues with aviation and security experts, in an interactive format. Administration and the Pharmaceutical Industry.
• Gain a better understanding of the global regulatory environment
What you will learn: • Evaluate current options available for meeting TSA screening mandates
• Options for meeting the U.S. governments 100% screening mandate • Collaborate with the experts to develop new approaches
• Case Study: Innovative approaches that are currently being taken in the • Understanding how to balance supply chain issues to deliver more value in Cold-
Pharmaceutical Industry
Chain shipment transport
• New IATA regulations surrounding international transport
Choose from Workshop G or H
• Navigating importation and customs issues
Your Workshop Leader:
• Keys to maximizing success in cold-chain transport
Dave Brooks, President, American Airlines Cargo
5:45 pm – 8:45 pm Registration at 5:30 (Dinner will be served)
H Assembling the Puzzle: A New Paradigm in Clinical Supplies Distribution
Challenges that are unique to the distribution of clinical supplies place high • Use of Containers
demands on a Company’s technology line-up. The ability to deliver sustainable • Taking a closed loop approach to the use of containers
results is contingent upon creating achievable goals, selecting proper tools, and
How you will benefit:
leveraging cross-functional supply chain capabilities. By understanding the • Gain an understanding of operating challenges related to Clinical Trials
distribution pathway, you are able to take action that mitigates risks during supply • How Stability Data can be appropriated
chain handoffs, thereby achieving higher levels of compliance. • See how data loggers suit your approach
This workshop provides the details of success experienced in Schering-Plough’s • Realize the advantages during container selection
global supply chain. • Better understand instances for closed-loop-distribution
What you will learn:
Your Workshop Leaders:
• Considerations for Shipping Tools in Clinical Applications
Kevin Grimm, Engineer, Schering-Plough
• Understanding and Leveraging Stability Data
Vincent Porzio, Engineering & Technical Services Manager, Schering-Plough
• Use of Data Loggers
Amlan Dutta, Engineering & Technical Services Director, Schering-Plough
6 www.coldchainpharma.com Sponsors:
7. Main Conference Day One
Tuesday, September 22, 2009
7:00 Registration and Coffee • How has global economics affected the airline industry?
• What changes in the airline industry do you see that may affect cargo
8:00 Pharma IQ Welcome capacity?
Panelists:
8:05 Opening Remarks from Conference Chairperson Jack Lo
Rafik H. Bishara, PhD Cargo Product and Marketing Manager
Technical Advisor and Chair PCCIG USA Branch Cathay Pacific Cargo
PDA Stephane Lemaire
Director Pharmaceutical Logistics
Transportation and Logistics Air France KLM Cargo
8:15 Introductory Remarks from Plenary Chairperson Don Harrison
Project Manager, Product Development
Kevin O'Donnell United Airlines Cargo
Director & Chief Technical Advisor, Tegrant Corp., ThermoSafe Brands &
Chair A Representative
IATA Time & Temperature Task Force Air Canada Cargo
8:25 KEYNOTE: Meeting US Security Standards and Qualifying 10:45 Morning Networking Break
for the TSA Screening Program to Avoid Custom Delays
• Program background, motivations and looming deadlines 11:30 Standardizing Qualification and Auditing of Transportation
• How to prove Chain of Custody: Documentation, application ad and Warehousing Partners
authentication • Defining quality parameters and expectations of our transportation partners
• Case stories of biopharma company compliance • Streamlining transportation agreements across partners
• Freight forwarders qualification requirements • Central Eastern Europe Case Study: Certifying new warehouse and
transport suppliers
Edward J. Kelley • Feedback on the best practice guidance document from the PCCIG
General Manager for Air Cargo, Transportation Security Steering Committee on Standardizing Qualification of 3PLs
Administration
Department of Homeland Security Arminda O. Montero
Distribution QA Program Manager, Global Pharmaceutical Operations
9:05 Panel Discussion: Panel Navigating the New TSA Abbott
Requirements –Why a Layered Risk-Based Approach to Air
Cargo Security Provides the Best Model for Safely 12:10 Case Study: Using Advanced Predictive Thermal Modeling
Shipping Pharmaceuticals to Determine the Acceptable Product Payload
• Why does a layered risk-based approach make sense? Characteristics for a Shipping Lane with a Defined Ambient
• What innovative steps are being taken to adapt to the 100 percent Temperature Profile
screening environment? Pharmaceutical manufacturers ship a wide variety of thermally sensitive
• How will supply-chain value be impacted for Pharmaceutical shipments? products to various locations around the world. As such, it becomes
impractical for these companies to perform operational qualification (OQ)
Panelists: studies for all combinations of product that could possibly be shipped inside
David R. Brooks an existing shipper design. This presentation will discuss how advanced
President thermal modeling software is applied to define the acceptable product load
American Airlines Cargo characteristics in such a way that they can be applied to multiple products,
Edward J. Kelley and how to define those characteristics analytically.
• Bracketing payload characteristics: thermal mass (product density), product
General Manager for Air Cargo, Transportation Security
Administration type (liquid, lyophilized), volume (syringe, vial) and quantity of product
• Using analytical modeling to derive and bound acceptable product load
Department of Homeland Security
characteristics for an existing shipper in a given shipping lane with a
Brad Elrod defined ambient temperature profile
Senior Manager, Global Logistics Security • Verifying and validating the thermal models through physical testing once
Pfizer the worst-case configurations representing the load limits are selected
• Predicting how an existing shipping solution will perform and how the drug
9:55 ‘Interview with an Airline’ Panel Discussion: Meeting IATA product will be affected when subjected to new, potentially more severe,
Chapter 17 Revised Regulations and Biopharma ambient temperatures
Requirements for Temperature Sensitive Products • Understanding how the analytical model can provide insight into the critical
Reducing transportation costs while shipping temperature sensitive effects of convection, conduction and refrigerant phase change inside the
pharmaceuticals in a timely fashion is a balancing act for cold chain shipper
professionals. Rapid air transport is a desirable and sometime necessary
mode, but biopharma companies still wonder ‘can the airline effectively Jeffrey Simpson
handle my shipments?’ or ‘how do I know air carriers are taking all the Director of Engineering and Technical Services
necessary precautions to ensure temperature controls?’ This session will Cold Chain Technologies
‘interview’ airlines handling temperature controlled biopharma products Geoffrey Glauser
including discussion on: Director of Global Packaging Technology
• What evidence can be provided to biopharma customers to document any
Wyeth Pharmaceuticals
temperature deviations at the airport?
• What does a Quality Management System mean to you and how has your
12:50 Optimizing Logistics Modeling: Maximizing On Time
airline implemented it? Delivery Performance
• What strides have you made to comply with the new Time and
Cold chain products have unique characteristics challenging the traditional
Temperature Label usage requirements? supply chain. The primary purpose of an optimized logistics model is to
• What other programs or process have airlines implemented to reduce
deliver the therapy to the patient when it is expected, while protecting the
environmental risks to time and temperature-sensitive healthcare integrity of the product. This discussion will concentrate on the supply chain
products?
7
8. from origination to delivery to the patient and the various reasons why and exceptions by delineating between internal and external causes of
deliveries are not made, the financial impact, and a solution to detect, service delays
troubleshoot, intercept and provide delivery. Discussion points will include • Establish optimized distribution modeling for maximum on time delivery
opportunities to optimize your mode of transportation, reducing performance
transportation and packaging spend, and meeting customer’s delivery • Define process which can be employed to control seemingly
expectations. Additionally, processes to evaluate root cause analysis of uncontrollable service delays such as weather and consignees not being
these delivery exceptions and corrective action implementation to minimize available
future / repeat occurrences will be outlined. This discussion aims to:
• Present industry best in class processes to analyze current distribution Josh A. Hobick
Senior Vice President
patterns and determine opportunities for service improvement and cost
Dawson Logistics
avoidance. (Improve on time service to your patience and reduce reships)
• Demonstrate analytical applications to realize root cause of service gaps
1:30 Networking Luncheon
Concurrent Sessions begin: Choose Track A or B
Track A: Biologic Materials & Clinical Supplies Track B: Last Mile Cold Chain Logistics
2:40 Addressing Cold Chain Logistical Challenges within the Distribution of Cold Chain Products to the Public and
Military Blood Program Emergency Planning
• Evaluation and determination of need • Challenges to ensure temperature control in the public health arena
• Assessing the environment • Preparing for mass immunizations
• Proper methods of data gathering and analysis • Defining optimal levels of stock piles and ‘ready to dispense’ logistics
• Defining requirements for specific products • Working with the CDC and government agencies for pandemic
• Evaluating solutions and available options emergency scenarios
• Developing a plan for implementation and success
Dr. Lisa Kaplowitz
• Lessons learned in this type of process.
Public Health District Leader, Alexandria, Virginia,Former
US Military speaker pending final approvals Deputy Commissioner for Emergency Preparedness and Response
State of Virginia
3:25 Global Logistics for the Clinical Distribution of Cytotoxic Role of the Wholesaler in the Distribution of
Antibody-Drug Conjugates Temperature-Controlled Products
• Introduce the unique characteristics and requirements for ADC molecules • Updating processes and practices to monitor required temperatures
• How to establish and qualify multiple legs of the cold chain from US of biopharma products
to EU and back to US • Visibility and temperature control after leaving warehouse depot
• Challenges with maintaining and monitoring temperature: • Preparing to meet Health Canada regulatory expectations for 0069
• Establishing qualified storage sites in Europe for distribution guidelines
• Import/export logistics; customs, compliance and VAT considerations • Addressing how McKesson is meeting industry standards and
• Packaging and safety measures for highly toxic, potent materials technical guidance
Joanna Ward Claude Jolicoeur
Senior Director, Manufacturing and Supply Chain Management Director of Regulatory Affairs and Corporate GMP Officer
Seattle Genetics McKesson Canada Corp.
4:05 Afternoon Networking Break
4:35 Cold Chain Planning and Shipping of Bulk Protein Setting up International Transport and Logistics to New
Internationally at -60°C Markets
• Developing supply chain options for highly volatile demand forecast • Designing new transportation routes and temperature profiles
• Establishing large volume shipping containers for biotech material • Evaluating modes of transport for certain lanes
stored at -60C • Preparing for 0% allowable excursions in some countries such as
• Assessing and developing new pallet shippers to hold maximum Mexico or Brazil
material, maintaining temperature and minimizing cost • Evaluating packaging technology and logistic partners for global routes
• Understanding customs controls in emerging countries with unusual
Christina Pavlik regulations
Manufacturing Planning Manager
Novartis Anthony Moran
Director of Procurement
Siemens
5:20 Quality Control for the Storage and Transportation of Panel Discussion: Achieving Greater Visibility into Cold
Blood and Biologics Chain Control and Compliance Post-Manufacture
• Developing shipping protocols for the blood supply chain • Assessing requirements including validation master plan, routes,
• Conducting qualification processes according to GDP requirements timelines to ensure an effective cold chain
• Temperature maintenance for international transport of blood to • Qualifying shipping systems and assessing suitability
Australia and Europe • Adopting a bracketing approach to cold chain validation studies
• Qualification of boxes for longer shipping times • Discussing Industry Standards guidelines and their application to
• IATA Chapter 17 new developments for shipment of biologics, controlling your downstream cold chain
including training for active systems
All Track B speakers and participants are invited to join the discussion
Boriana Cavicchia
Manager, Systems Quality, BioMedical Services
American Red Cross
6:00 Closing Remarks
6:10 Networking Cocktail Reception in Exhibition Hall
Join your colleagues from across disciplines to exchange ideas
and network in an informal environment. Take this time to
learn from the industry’s top technology and logistics providers
to update and advance your cold chain management.
8 www.coldchainpharma.com Sponsors:
9. Main Conference Day Two
Wednesday, September 23, 2009
7:45 Registration and Coffee practices in protecting materials from exposure to temperatures outside
recommended storage conditions and evaluating the impact of such
Regulatory Compliance exposures when they do occur.
Bob Seevers
8:30 Opening Remarks from Chairperson Principal Regulatory Scientist, Regulatory Affairs, CMC
Rafik H. Bishara, PhD Eli Lilly and Company
Technical Advisor and Chair PCCIG USA Branch
PDA 11:40 Biopharma Temperature Control Industry Best Practice
Initiatives
8:35 European Regulatory Guidelines: Controlled or Ambient The leadership of the Pharmaceutical Cold Chain Interest Group (PCCIG)
Temperatures, Stability Data and Compliance continues post publication of PDA Technical Report No. 39. This
• Expectations and documenting for ambient or CRT products presentation will review progress being made for the Industry Best Practices
• Regulatory expectation for qualification or validation in multiple project areas including:
• Last Mile for the distribution of pharmaceutical products to the end-user
• Stability studies versus shipping studies -are stability studies enough to
• Good Distribution Practices (GDPs) for the pharmaceutical supply chain
set the limits for your cold chain?
• Mean Kinetic Temperature (MKT)
Ian Holloway • Active system temperature profiling
Manager, Defective Medicines Report Centre • Global regulatory requirements
MHRA • Harmonized labeling for cold chain
• Distribution Validation Master Plan (VMP)
9:10 Health Canada's Guidelines on Monitoring Temperature • Supply Chain Partner Management best practices
Control of Drug Products in the End to End Cold Chain • From the first to the last mile
• Proposed revisions to Health Canada's GUI-0069
• Wholesaling, storage and shipping Rafik H. Bishara, PhD
• Regulatory expectations for temperature control of drug products Technical Advisor and Chair PCCIG USA Branch
• Common questions and misconceptions regarding temperature control PDA
of drug products
12:15 Ask the Regulator and Industry Panel Discussion
Sarah Skuce • Lessons learned in justifying pharma company actions and validation plans
Compliance Specialist to regulators – what exactly demonstrates control?
Health Canada • New regulations on storage, handling and distribution of drug samples &
mail-order drugs
9:45 Understanding and Applying the USP <1079> Revised • Extrapolating future regulatory requirements in-line with cold chain trends
Guidelines
• Outlining the new 1079 Chapters for implementation (Anonymous questions may be submitted to the panel before hand by
• Understanding 1079’s definition of validation (for packaging) and sending to courtney.becker@iqpc.co.uk)
comparing to other industry standard guidelines Moderator:
• Specific protocols for receiving, shipping and storing temperature Rafik H. Bishara, PhD
controlled pharmaceuticals Technical Advisor and Chair PCCIG USA Branch
• Using examples and grids to demonstrate how to use the guidance to PDA
make decisions for your cold chain management
Panelists:
Dr. Mary Foster Ian Holloway
USP Packaging and Storage Expert Committee Member Manager, Defective Medicines Report Centre
US Pharmacopeia (USP) MHRA
10:20 Morning Networking Break Sarah Skuce
Compliance Specialist
11:05 Regulatory Points to Consider for Cold Chain Distribution Health Canada
With the increasing trend toward using more third party resources to
Dr. Mary Foster
manufacture and distribute drug products, the identification and control of
USP Packaging and Storage Expert Committee Member
risks encountered in the distribution environment have evolved into a
US Pharmacopeia (USP)
major element in the process of storing and shipping pharmaceuticals. The
WHO, PDA Technical Report 39, and FDA have all identified that the Bob Seevers
holding of drugs includes distribution and is seen as a cGMP regulated Principal Regulatory Scientist, Regulatory Affairs, CMC
process. This presentation will use the principles presented by global Eli Lilly and Company
regulators to provide recommendations and note current industry best
1:00 Networking Luncheon
Concurrent Sessions begin: Choose Track A or B
Track A: QA Distribution & Risk Management Track B: Cold Chain Packaging and Materials
2:00 Developing a Risk Model and Tool for the Evaluation of Understanding Green Packaging Solutions for Your
Shipping Practices Business and Cold Chain
• Tightening the risk management process by adding more control in • Cost vs. environmental impact vs. ‘reward’
the front end to ensure maintenance of product quality throughout • Logistics practicalities of recycling of temperature controlled packout
the distribution supply chain components: Expanded polystyrene’, gel packs, bubble wrap,
• The risk grid defines acceptable risk by utilizing several key factors that cardboard, etc.
compose the shipping process • Assessing options for non-dry ice solutions for frozen packout
• Based on the outcome of the risk classification performed, the requirements
shipping requirements for each product type and/or product family can • Biodegradable packaging considerations & suppliers
be determined
9
10. Gwyn Murdoch Ms. Betsy Steiner
Quality Manager, Materials/Packaging Quality Systems Executive Director
Eli Lilly Alliance of Foam Packaging Recyclers
2:40 Risk-Based Evaluation of Cold Chain Issues for Operational Qualification of an Active Heating and
Effective Supply Chain Distribution Management Cooling Air Cargo Container, a considered approach:
Effective risk management of cold chain issues with the distribution • What parameters should be considered during the design
network of a supply chain requires consideration of several challenging qualification?
elements including regulatory, logistics, financial and operational • How does one handle the concepts of repeatability and consistency?
considerations. Balancing these often contradictory constraints and • Should active container qualifications be compared to passive
implementing an optimal logistics solution is an iterative challenge that container qualifications?
requires on-going evaluation and adjustment. The session will include • What technical considerations should be covered in the laboratory
several “case studies” and practical examples of the types of risk qualification, field qualification?
mitigation steps to avoid losses from spoilage, contamination, and
Geoffrey Glauser
other temperature-driven issues.
• Transportation vendor vetting, collaboration and review
Director of Global Packaging Technology
• Negotiation to incorporate SOP’s directly into a logistics contract
Wyeth Pharmaceuticals
• Critical challenges in the selection and management of
transportation vendors and the implementation of control elements
• Threat/exposure identification of cold chain transit risk elements
• Effective contingency planning for specialized cold chain processes
Eric Newman
Vice President, Loss Prevention
Falvey Cargo Underwriting
3:15 Afternoon Networking Break
3:45 Temperature Controlled Transportation and QA Case Case Study: Qualifying an Active Heating/Cooling
Study System
Logistics and Quality personnel engage in daily and periodic activities to • Using a Failure Mode Evaluation to evaluate potential risks of the
ensure the maintenance of a robust cold chain management system. new system
These activities support initial vendor qualification, packaging • Qualification testing performed in the lab
component validation, packout design and qualification, and other • Working with freight forwarders to develop SOPs for handling
components of the Quality System that impact cold chain management. processes at airport
This session of will focus on how evolving industry practice and • Conducting trial runs and collecting temperature data
available guidance in cold chain management, increased scrutiny of • Assessing the cost – benefit of the new system
drug safety and corporate focus on waste reduction necessitate the • Current status
efficient management of relationships, risk, and processes to ensure
Rose Bicksler
appropriate stewardship and control of drugs in the supply chain.
• Managing partner relationships to ensure compliance and effective
Senior Manager, Global Quality Assurance and Validation
Global Pharmaceutical Supply Group
processes
Johnson & Johnson
- Working with 3PLs to ensure back up systems and plans are in
place for our warehouses
- Contingency planning with carriers
- Ensuring risk mitigation procedures are in place
• Re-evaluating cold packaging to extend shipping stability time and
balance with the most cost-effective transportation modes
Clint Pollard
Manager, Transportation
Merial Animal Health
Zachery Thompson
Manager, Quality Systems, Global Quality
Merial Animal Health
4:25 Panel Discussion: Defining Stability Profiles and Panel Discussion: Defining the Future of Temperature
Extrapolating Correct and Sufficient Stability Data to Controlled Packaging for Biopharmaceuticals
Cover Temperature/Time Excursions • Balancing increasingly higher value medicines with cost-reduction
• How low can you go: How flexible can stability profiles be to remain pressures
compliant? • Comparing EPS , PUR and VIP packaging
•
Understanding varying country regulatory ‘allowable excursions’ • Rapid Evaporation Technology – 5 or 10 years away?
•
Defining what to put in regulatory file • Myths and realities of returnable /recycling programs
•
Communication to regulators • Other emerging technologies?
•
Assembling regulatory package
Ms. Betsy Steiner
•
Using a general acceptable approach in practice to handling
Executive Director
deviations and excursions
Alliance of Foam Packaging Recyclers
Ian Holloway
Geoffrey Glauser
Manager, Defective Medicines Report Centre
Director, Cold Chain Technology
MHRA
Wyeth
Bob Seevers
Rose Bicksler
Principal Regulatory Scientist, Regulatory Affairs, CMC
Senior Manager, Global Quality Assurance and Validation,
Eli Lilly and Company
Global Pharmaceutical Supply Group
Henry Ames Johnson & Johnson
Director of Strategic Marketing
Sensitech
5:00 Closing Remarks
10 www.coldchainpharma.com Sponsors:
11. Clinical Logistics Focus Day
Thursday, September 24, 2009
8:15 Registration and Coffee 1:50 Boosting Clinical Trial Efficiency by Outsourcing
Clinical Logistics to Global Partners
8:50 Opening Remarks by Chairperson In late 2006, Wyeth Research and DHL Deutsche Post signed a
strategic agreement with the intent to have DHL serve as the
9:00 Planning and Management of Pfizer’s International primary preferred carrier in the shipment of test articles, ancillaries
Clinical Supply Distribution and other supporting materials. In the session, the discussion will
• Preparing for key country regulatory approvals focus upon key attributes of the relationship, as well as highlighting
• Managing export/import challenges and risks for efficient customs some current and future technological and operational
clearance enhancements that continues to flourish in this dynamic relationship.
• Outsourcing considerations for our clinical logistics The outcome has been very successful for both companies, with
• Setting up effective partnerships and alliance structures emphasis on planning between key stakeholders, versus
• Monitoring cold chain products and biologicals conventional transaction-related freight.
• Decision factors in outsourcing clinical logistics
Catherine Hall • Steps for building a global alliance with preferred partners
Supply Chain Coordinator • Defining SOPs and KPIs
Pfizer Global Research and Development • Implementing effective service and quality agreements
• Extending global reach and finding additional cost-cutting
9:40 Case Study: Managing a Massive Large Scale Vaccine opportunities and services by moving from 3PL partnerships to 4PL
Clinical Trial • Advanced temperature control packaging choices for our clinical
•
Delivering positive results by using risk management, contingency supplies
and mitigation planning for offsetting challenges of international • Establishing 'chain of custody' of our clinical supplies internally and
transportation routes and potential delays. with our global partner
• Value of effective partnerships and leveraging core expertise to • Implementing innovative methods to track temperature and
further mutual objectives location, providing data points for overall supply chain database
• Changing distribution models as recruitment rates fluctuate and
resources shift. How risk drives innovation to deliver. outstanding Bruce T. Guenter
performance with challenging temperature profiles and shipping Director, Global Materials Logistics
conditions Wyeth Research
• Using Project management as a tool to solve the challenging
aspects of a large study 2:30 Afternoon Networking Break
C. Ray Goff, Jr. 3:00 Best Practices to Improve Patient and Clinical Site Cold
PMP, CPM, PMM, Director of Vaccine R&D
Chain Compliance
Wyeth • Qualifying if clinical supply chain partners have sufficient
refrigeration or systems
10:20 Morning Networking Break • How to maximize ability of patient to maintain necessary
temperatures of their medications
10:50 My Temperature Sensitive Product Deviated for 2 • Labeling of investigational supplies best practices and examples
hours: Making Quick Decisions on How to Handle that ensure patient compliance
Temperature Excursions for Clinical Materials • Project management aspects that help improve cold chain
• Developing a proactive stability database compliance downstream
• Building procedures that qualify if materials are still viable
• Avoid recalling products, repeated processes and lengthy QA David Bernstein
investigation processes Vice President, Pharmaceutical Sciences and Regulatory Compliance
• Examples of deviations and proactive responses Bernstein CMC Regulatory Consulting
David Bernstein 3:35 Considerations for Shipping Comparators to
Vice President, Proactive Damage Control
International Markets
Bernstein CMC Regulatory Consulting • Working with vendors to understand new markets for clinical sites
• Cold chain concerns and temperature monitoring for comparators
11:25 Panel Discussion: Preparing for International Clinical • Temperature control packaging: Cost, IVRS systems and cooling
Cold Chain Regulatory Requirements methods
• Meeting EU Clinical Directive requirements • Shipping to international sites and dealing with depot
• Challenges shipping into Latin America: Key partners and management
overcoming import/export roadblocks
Douglas Hawley
12:10 Networking Luncheon IM Operations Sr. Specialist, Global Logistics
Celgene Corp.
1:10 Implementing Automated Temperature Monitoring to
Improve Clinical Distribution Processes 4:10 Clinical Material Packaging, Labeling and Distribution:
• Eliminate manual data entry and review of data from every From Factory to Clinic
shipment utilizing the ELPRO data logger • Choosing appropriate packaging for bulk supplies and small vials
• Programming the data logger for other shipments
• Making data available worldwide to communicate temperature • Using IVRS to ensure minimal loss of supplies by having two-way
deviations integration between shipper and IVRS
• Reducing guesswork wit early phase materials with little data • Implementing cold chain strategies that ensure minimal
distribution to clinical trials
Vincent Porzio
Clinical Supplies Manager Michele Alm
Schering-Plough Supply Chain Manager
Fibrogen
4:45 Closing Remarks
11